HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii.

AbstractOBJECTIVES:
To investigate the clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii (MDRAB).
METHODS:
A retrospective observational study over a 32-month period for adult patients receiving tigecycline treatment at least 7 days for pneumonia involving MDRAB.
RESULTS:
We reviewed 112 patients with 116 episodes of tigecycline-treated pneumonia involving MDRAB. The mean age was 70.8 years. The mean Acute Physiology and Chronic Health Evaluation (APACHE) II score was 21.7. Seventy episodes (60.3%) had clinical resolution. The episodes with monomicrobial MDRAB pneumonia had a significantly lower clinical resolution rate than polymicrobial pneumonia (14/31, 45.2% vs. 56/85, 65.9%; p = 0.044). The independent predictors for failure of clinical resolution were female gender, malignancy, bilateral pneumonia, monomicrobial pneumonia, and higher APHCHE II scores. Forty-two episodes (36.2%) had the 30-day mortality, and the only independent predictor was deterioration of pneumonia on chest radiographs.
CONCLUSIONS:
A high disease severity, bilateral pneumonia, and monomicrobial MDRAB pneumonia predicted failure of clinical resolution, and deterioration of pneumonia predicted mortality. MDRAB in monomicrobial pneumonia was the most certain to be causal. The clinical resolution rate from such pneumonia might reflect the ultimate efficacy of tigecycline in treating MDRAB pneumonia and the overall efficacy might be overestimated.
AuthorsJung-Jr Ye, Huang-Shen Lin, An-Jing Kuo, Hsieh-Shong Leu, Ping-Cherng Chiang, Ching-Tai Huang, Ming-Hsun Lee
JournalThe Journal of infection (J Infect) Vol. 63 Issue 5 Pg. 351-61 (Nov 2011) ISSN: 1532-2742 [Electronic] England
PMID21846481 (Publication Type: Journal Article)
CopyrightCopyright © 2011 The British Infection Association. All rights reserved.
Chemical References
  • Anti-Bacterial Agents
  • Tigecycline
  • Minocycline
Topics
  • APACHE
  • Acinetobacter Infections (drug therapy, mortality)
  • Acinetobacter baumannii (drug effects)
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents (therapeutic use)
  • Bacteremia (drug therapy)
  • Demography
  • Drug Resistance, Multiple, Bacterial
  • Female
  • Humans
  • Male
  • Middle Aged
  • Minocycline (analogs & derivatives, therapeutic use)
  • Pneumonia, Bacterial (drug therapy, mortality)
  • Prognosis
  • Retrospective Studies
  • Severity of Illness Index
  • Sex Factors
  • Tigecycline
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: